Shire To Participate At The Piper Jaffray 27th Annual Healthcare Conference
LEXINGTON, Massachusetts, November 24, 2015 /PRNewswire/ --
Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that Jeff Poulton, Chief Financial Officer, will participate in the Piper Jaffray 27th Annual Healthcare Conference in New York City, NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT).
A live audio webcast will be available on the Presentations and Webcasts section of Shire's Investor website at http://investors.shire.com/presentations-and-webcasts/. Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
http://www.shire.com
For further information please contact:
Investor Relations,
Matt Osborne, mattosborne@shire.com, +1-781-482-9502
Sarah Elton-Farr, seltonfarr@shire.com, +44-1256-894157
SOURCE Shire plc
Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that Jeff Poulton, Chief Financial Officer, will participate in the Piper Jaffray 27th Annual Healthcare Conference in New York City, NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT).
A live audio webcast will be available on the Presentations and Webcasts section of Shire's Investor website at http://investors.shire.com/presentations-and-webcasts/. Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
http://www.shire.com
For further information please contact:
Investor Relations,
Matt Osborne, mattosborne@shire.com, +1-781-482-9502
Sarah Elton-Farr, seltonfarr@shire.com, +44-1256-894157
SOURCE Shire plc